MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-05-2026
Minerva Neurosciences ROCE Ratio 2011-2026 | NERV
Annual ROCE Ratio Minerva Neurosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.73 | 85.04 | 81.24 | 126.0 | -568.8 | 3.39 | -107.05 | -38.17 | -23.28 | -24.49 | -33.8 | -84.49 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 126.0 | -568.8 | -47.81 |
Quarterly ROCE Ratio Minerva Neurosciences
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 33.52 | 32.12 | 52.27 | 64.2 | 67.8 | 52.52 | 82.85 | 93.02 | 115.04 | 86.55 | 123.1 | 129.33 | 176.29 | 1204.95 | 1178.18 | 1114.85 | 1006.98 | -68.1 | -81.96 | -70.55 | 10.26 | 3.51 | -99.15 | -135.2 | -237.68 | -273.1 | -171.68 | -134.03 | -101.91 | -57.31 | -49.46 | -44.36 | -37.44 | -31.28 | -32.76 | -31.86 | -29.14 | -28.49 | -34.58 | -37.13 | -43.89 | -47.2 | -46.84 | -89.25 | -112.08 | -106.54 | -102.21 | -51.88 | -19.48 | -14.39 | -4.27 | -1.88 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1204.95 | -273.1 | 61.54 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K |  USA |
 |
Exelixis
EXEL
|
40.35 | $ 48.43 | 9.03 % | $ 13.2 B | USA |
 |
Fortress Biotech
FBIO
|
-140.8 | $ 2.56 | 3.96 % | $ 71.4 M | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Galapagos NV
GLPG
|
-3.51 | $ 28.78 | 1.36 % | $ 2.69 B |  Belgium |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B | France |
 |
Genmab A/S
GMAB
|
31.74 | $ 27.93 | 1.41 % | $ 17.2 B |  Danmark |
 |
Genprex
GNPX
|
-194.87 | $ 0.9 | 2.02 % | $ 839 K | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Grifols, S.A.
GRFS
|
7.15 | $ 8.41 | 1.69 % | $ 6.83 B |  Spain |
 |
Athira Pharma
ATHA
|
-368.0 | - | - | $ 269 M | USA |
 |
InflaRx N.V.
IFRX
|
-24.77 | $ 2.47 | 25.39 % | $ 152 M | Germany |
 |
Ionis Pharmaceuticals
IONS
|
-43.85 | $ 76.96 | 2.27 % | $ 12.3 B | USA |
 |
Kamada Ltd.
KMDA
|
10.36 | $ 8.3 | 1.1 % | $ 260 M |  Israel |
 |
BioNTech SE
BNTX
|
-4.81 | $ 95.07 | -0.45 % | $ 27.2 B | Germany |
 |
Kymera Therapeutics
KYMR
|
-22.12 | $ 86.14 | 4.15 % | $ 7.28 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.5 | - | - | $ 231 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
-2.72 | $ 229.83 | -1.06 % | $ 4.2 B | USA |
 |
INmune Bio
INMB
|
-201.42 | $ 1.52 | -1.3 % | $ 37.6 M | USA |
 |
Liquidia Corporation
LQDA
|
-114.81 | $ 41.84 | 4.26 % | $ 3.6 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
-7.03 | $ 107.42 | 1.52 % | $ 5.39 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
31.5 | $ 22.32 | -0.13 % | $ 3.7 B | USA |
 |
MannKind Corporation
MNKD
|
-76.05 | $ 3.68 | 28.5 % | $ 1.12 B | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Nanobiotix S.A.
NBTX
|
-31.68 | $ 42.28 | 21.6 % | $ 286 B | France |
 |
Esperion Therapeutics
ESPR
|
-19.96 | $ 3.13 | 0.55 % | $ 651 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 3.47 | -8.44 % | $ 5.71 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
-116.14 | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 23.86 | 1.88 % | $ 3.04 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-252.54 | - | 3.16 % | $ 1.9 M | USA |
 |
Puma Biotechnology
PBYI
|
28.62 | $ 7.5 | 2.04 % | $ 375 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-75.24 | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.41 | - | - | $ 2.17 B | USA |